Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Leigh MacConell PhD Appointed Chief Development Officer of High Tide Therapeutics: To Lead the Company’s Global Clinical Development

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Leigh MacConell PhD has over 20 years of drug discovery and development experience. Most recently Dr. MacConell served as Senior Vice President, Clinical Development at Intercept Pharmaceuticals where she provided strategic leadership for the global clinical development of obeticholic acid (OCA). Leigh MacConell, Ph.D. will report to Liping Liu, Ph.D., founder and CEO of HighTide Therapeutics.

Leigh MacConell PhD will lead the company’s global clinical development, regulatory and quality functions, and will focus on driving the advancement of the company’s pipeline.

“This year represents a significant step for HighTide as we transition to a late-stage clinical development company,” said Dr. Liu. “We are very pleased that Leigh has joined our team. She brings critical experience and proven leadership which can help us move our pipeline forward in numerous indications.”

“HighTide has developed an impressive and dedicated team that is focused on addressing unmet needs of patients around the world,” said Dr. MacConell. “I am excited about joining the company and helping them advance its growing and maturing pipeline of novel therapeutics.”

Prior to joining HighTide, Dr. MacConell led clinical development programs at Intercept Pharmaceuticals which secured US, EU and Canadian approvals of Ocaliva® for the treatment of primary biliary cholangitis (PBC), a rare chronic liver disease. She also was accountable for securing breakthrough status for OCA for the treatment of non-alcoholic steatohepatitis (NASH) with fibrosis and gaining consensus with US and EU regulatory authorities on precedent-setting clinical development plans in NASH.

Prior to Intercept, Dr. MacConell served as Senior Director, Medical Research and Development at Amylin Pharmaceuticals, which was acquired by Bristol-Myers Squibb, where she served as clinical lead of their Type 2 Diabetes portfolio, securing multiple approvals for the treatment of Type 2 Diabetes, globally. Dr. MacConell has a Ph.D. in neuroendocrinology from the University of California, San Diego.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine